Ignite Creation Date:
2025-12-25 @ 1:37 AM
Ignite Modification Date:
2025-12-28 @ 12:13 AM
Study NCT ID:
NCT04874194
Status:
TERMINATED
Last Update Posted:
2025-11-03
First Post:
2021-05-01
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-12-17
Start Date Type:
ACTUAL
Primary Completion Date:
2024-09-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-09-16
Completion Date Type:
ACTUAL
First Submit Date:
2021-05-01
First Submit QC Date:
None
Study First Post Date:
2021-05-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-07-31
Results First Submit QC Date:
None
Results First Post Date:
2025-11-03
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-20
Last Update Post Date:
2025-11-03
Last Update Post Date Type:
ESTIMATED